Open AccessComparison of New‐Onset Gout in Adults Prescribed Chlorthalidone vs Hydrochlorothiazide for Hypertension
Author(s) -
Wilson Liza,
Nair Kavita V.,
Saseen Joseph J.
Publication year - 2014
Publication title -
the journal of clinical hypertension
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.909
H-Index - 67
eISSN - 1751-7176
pISSN - 1524-6175
DOI - 10.1111/jch.12413
Subject(s) - medicine , chlorthalidone , hydrochlorothiazide , gout , ctd , diuretic , cohort , retrospective cohort study , thiazide , blood pressure , oceanography , geology
This study assessed the risk of new‐onset gout following prescribing of hydrochlorothiazide ( HCTZ ) compared with chlorthalidone ( CTD ). This retrospective cohort analysis used administrative claims from 2000 to 2012 to identify patients aged 18 to 89 years with hypertension who were prescribed CTD or HCTZ . Patients were excluded if they had a prior diagnosis of gout, conditions or prescription claims for medications that alter risk of gout, or if they switched between these two diuretics. A total of 1011 patients prescribed CTD were matched with 2022 patients prescribed HCTZ based on age, sex, and Chronic Condition Indicator. New‐onset gout occurred in 17 of 1011 (1.68%) patients in the CTD group and in 26 of 2022 (1.29%) patients in the HCTZ group ( P =.27). The number of days to first occurrence of gout was 183.6 days and 152.7 days in the CTD and HCTZ groups, respectively ( P =.39). The mean daily dose was 22.7 mg for CTD and 24.3 mg for HCTZ , and the median dose of both CTD and HCTZ was 25 mg at the time of new‐onset gout. Patients prescribed CTD for hypertension have a similar risk of developing new‐onset gout compared with patients prescribed similar doses of HCTZ .